16
Participants
Start Date
June 30, 2009
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
ST266
ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
University of Rochester, Rochester
Western Pennsylvania Hospital, Pittsburgh
Johns Hopkins Burn Center, Baltimore
Shands Burn Center at the University of Florida, Gainesville
University of South Florida / Tampa General Hospital, Tampa
University of South Alabama Dept. of Surgery, Mobile
MetroHealth Medical Center, Cleveland
Loyola University Medical Center, Maywood
Acute & Critical Care Surgery Barnes Jewish Hospital, Washington University Medical Center, St Louis
University of Missouri Health Care, Columbia
John S. Dunn Sr. Burn Center, Houston
LAC - USC Medical Center, Los Angeles
University of Kentucky Chandler Medical Center, Lexington
Brigham and Women's Hospital, Boston
Lead Sponsor
Noveome Biotherapeutics, formerly Stemnion
INDUSTRY